These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeted cancer therapy: promise and reality. Klein S; Levitzki A Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951 [TBL] [Abstract][Full Text] [Related]
4. New targets for non-small-cell lung cancer therapy. Alvarez M; Roman E; Santos ES; Raez LE Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567 [TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225 [TBL] [Abstract][Full Text] [Related]
6. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Tsao MS; Liu N; Nicklee T; Shepherd F; Viallet J Clin Cancer Res; 1997 Oct; 3(10):1807-14. PubMed ID: 9815567 [TBL] [Abstract][Full Text] [Related]
7. [Responses to targeted therapies: colorectal cancer]. Bibeau F; Frugier H; Boissière-Michot F Ann Pathol; 2009 Nov; 29 Spec No 1():S74-6. PubMed ID: 19887260 [No Abstract] [Full Text] [Related]
9. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo. Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363 [TBL] [Abstract][Full Text] [Related]
10. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Dovedi SJ; Davies BR Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963 [TBL] [Abstract][Full Text] [Related]
12. Exploring the future of non-small cell lung cancer treatment. Ramalingam S Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956 [No Abstract] [Full Text] [Related]
13. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene]. Francoz S; Dubus P Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418 [No Abstract] [Full Text] [Related]
14. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182 [TBL] [Abstract][Full Text] [Related]
15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Sangha R; Lara PN; Mack PC; Gandara DR Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Chi S; Kitanaka C; Noguchi K; Mochizuki T; Nagashima Y; Shirouzu M; Fujita H; Yoshida M; Chen W; Asai A; Himeno M; Yokoyama S; Kuchino Y Oncogene; 1999 Apr; 18(13):2281-90. PubMed ID: 10327074 [TBL] [Abstract][Full Text] [Related]
17. The role of targeted therapy in non-small cell lung cancer. Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252 [TBL] [Abstract][Full Text] [Related]
18. Interventions that induce modifications in the tumor microenvironment. Bernhard EJ Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567 [TBL] [Abstract][Full Text] [Related]
19. Overview of novel anticancer drug targets. Buolamwini JK; Assefa H Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193 [No Abstract] [Full Text] [Related]
20. Targeted therapies in lung cancer. Besse B; Ropert S; Soria JC Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566 [No Abstract] [Full Text] [Related] [Next] [New Search]